How to Navigate Start-up Costs to Innovate Patient Care

September 2018

Clinical trial start-up costs, plagued by systemic inefficiencies and antiquated data collection, are a chronic issue for the life sciences industry, with the potential to threaten its future viability. And, according to a new study by the Tufts Center for the Study of Drug Development, mounting costs are showing little sign of improvement. To alleviate these chronic issues, some organizations are looking to technology for an answer.

 “New technologies and approaches are promising to create efficiencies. We’re seeing larger, more collaborate studies emerge,” Su Linna, managing director in BDO’s Industry Specialty Services and Life Sciences Practices, told CenterWatch. Federal, state and grant funding options, meanwhile, “can help companies defray costs.”

Learn more about how CROs making investments in tech are getting trials done faster.